![Frontiers | CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy Frontiers | CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy](https://www.frontiersin.org/files/MyHome%20Article%20Library/410152/410152_Thumb_400.jpg)
Frontiers | CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
![Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model](https://www.mdpi.com/cells/cells-12-00507/article_deploy/html/images/cells-12-00507-g009.png)
Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
![Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model](https://www.mdpi.com/cells/cells-12-00507/article_deploy/html/images/cells-12-00507-g001.png)
Cells | Free Full-Text | Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
![RCSB PDB - 7LM9: Crystal structure of SARS-CoV spike protein receptor-binding domain in complex with a cross-neutralizing antibody CV38-142 Fab isolated from COVID-19 patient RCSB PDB - 7LM9: Crystal structure of SARS-CoV spike protein receptor-binding domain in complex with a cross-neutralizing antibody CV38-142 Fab isolated from COVID-19 patient](https://cdn.rcsb.org/images/structures/7lm9_model-1.jpeg)